Walnut Creek, CA, United States of America

Stephen Fitzhugh Carroll

This inventor holds 30 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 1 EPO patent, primarily in Immunotoxins Research. Top assignees: Xoma Corporation, Igm Biosciences, Inc., Xoma Technology Ltd.. Active years: 1992-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Stephen Fitzhugh Carroll. Retrieved from https://idiyas.com/inventor/stephen-fitzhugh-carroll

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 30 

% Patents Active = 90.0

 

 

Average Co-Inventor Count = 2.6

ph-index = 11

Forward Citations = 266(Granted Patents)


Company Filing History:


Years Active: 1992-2022

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Immunotoxins
Hepatitis B
Binding Molecules
Ribosome-Inactivating Proteins
Bactericidal Proteins
Lipopolysaccharide
Quantification Methods
Polynucleotides
Therapeutic Uses
Multi-Valent
Fusion Proteins
Inflammatory State
30 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Stephen Fitzhugh Carroll

Introduction

Stephen Fitzhugh Carroll is a notable innovator based in Walnut Creek, California. With a significant portfolio of 30 patents, Carroll has made remarkable contributions to the field of biotechnology, particularly in the development of binding molecules for medical applications.

Latest Patents

Among his latest innovations, one notable patent focuses on multi-valent hepatitis B virus antigen binding molecules. This patent provides the framework for a multimeric hepatitis B virus (HBV) protein binding molecule, such as a dimeric IgA or a pentameric or hexameric IgM binding molecule. It includes at least two bivalent binding units or their variants, each comprising at least two antibody heavy chain constant regions associated with an HBV antigen binding domain. Furthermore, the disclosure outlines compositions related to these multimeric binding molecules, polynucleotides that encode them, as well as methods for their production and applications.

Another important patent involves IgA multi-specific binding molecules. This innovation is particularly focused on the creation of multi-specific, including bispecific, binding molecules composed of IgA heavy chain sequences, highlighting the potential for advanced therapeutic treatments.

Career Highlights

Stephen Carroll has worked with notable companies such as Xoma Corporation and Igm Biosciences, Inc., where he furthered his research and development in the arena of antibody technologies. His work has significantly impacted the biotech landscape and has led to advancements in medical therapies.

Collaborations

Throughout his career, Stephen has collaborated with distinguished professionals, including Mark Leslie White and Marc D Better. These partnerships have fostered innovation and enabled the development of cutting-edge biotechnological solutions.

Conclusion

Stephen Fitzhugh Carroll stands out as a prominent inventor within the biotech sector, with a strong emphasis on immunology and therapeutic innovations. His extensive patent portfolio and collaborative efforts demonstrate his commitment to advancing medical science and the impact of his work on future healthcare solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…